"Generative AI is prone to produce hallucinations, and incorporating physics-based elements is a key approach to reducing them," commented CASUS. "As the AI-based quantitative phase imaging example ...

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and ...

The potential of the microbiome in disease treatment and prevention is an emerging and highly promising field in medicine. Research into microbiome-based therapies, such as probiotics, prebiotics, and ...

Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the ...

CytomX Therapeutics CTMX, a clinical-stage oncology company, is slated to report its fourth-quarter 2024 earnings results on ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on ...

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This ...

RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...